Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

axitinib

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

ABPI London offices

ABPI bid to overturn NICE’s budget impact rules fails

One in five new medicines would have been affected by the rejected policy

- PMLiVE

Janssen’s Imbruvica fails to win NICE backing in lymphoma

But the agency recommends it on the CDF for another type of cancer

- PMLiVE

Pfizer spins out SpringWorks Therapeutics biotech

Former Pfizer VP Lara Sullivan takes the helm at the newly-formed company

- PMLiVE

Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

Germany and the UK will be the first to receive the skin cancer treatment

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

- PMLiVE

NICE: We’re the institute of ‘yes’

But Meindert Boysen says affordability conversations with pharma need to happen earlier

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

NICE backs Europe’s first stem cell therapy

Holoclar is approved for routine use in patients with LSCD

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

FDA clears Pfizer’s leukaemia drug Besponsa

The breakthrough treatment is the first CD22-targeted ADC to be approved in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links